%A Li Jing, Huang Sanqian, Ouyang Quchang, Zhong Jingmin, Gao Nina, Liu Liping, Liu Zhihong, Zeng Liang %T Preliminary study on quantitative proteomic analysis of differentially expressed proteins in HER-2 positive and negative breast cancer %0 Journal Article %D 2016 %J Journal of International Oncology %R 10.3760/cma.j.issn.1673-422X.2016.10.001 %P 721-727 %V 43 %N 10 %U {https://gjzlx.sdfmu.edu.cn/CN/abstract/article_10057.shtml} %8 2016-10-08 %X ObjectiveTo seek differentially expressed proteins for human epithelial growth factor receptor2 (HER2) negative and positive breast carcinoma through establishing proteins profiles, and to provide new prognostic markers and therapeutic targets for patients with breast cancer. MethodsHER2 positive and negative breast cancer protein expression profiles were established using proteomic isobaric tags for relative and absolute quantitation (iTRAQ) technology. Differences of protein expression were identified and parts of differential expression proteins were analyzed by bioinformatics, including protein function annotation and GO classification analysis and Kyoto Encyclopedia of Gene and Genome (KEGG) pathway analysis. ResultsProteomic analysis of breast cancer tissue with identified HER2 positive and negative groups showed 4 999 differentially expressed proteins by iTRAQ. Based on the criteria of the ratio of HER2(+)/HER2(-)≥3, 119 upregulated proteins were identified in HER2 positive group. Based on the criteria of the ratio of HER2(+)/HER2(-)≤0.5, 47 downregulated proteins were identified in HER2 positive group. The results of GO analysis showed that the molecular function, biological process and cellular composition of differentially expressed proteins were complex between HER2 positive and negative breast cancer. There were differences in the distribution of upregulated proteins and downregulation of proteins. KEGG pathway analysis showed that differentially expressed proteins involved in 168 signal pathways. ConclusionThere are differentially expressed proteins between HER2 positive and negative breast cancer, which involve complex molecular function, biological process and signaling pathway.